La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Avid Bioservices a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Avid Bioservices..

Avid Bioservices (NASDAQ:CDMO) Azioni, Catena delle Opzioni

Avid Bioservices

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.

Avid Bioservices Inc

<p>Keefe, Bruyette &amp; Woods  analyst Paul Johnson   upgrades TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) from Underperform to Market Perform and lowers the price target from $8 to $7.5.</p>


News

Upgrades

Price Target

Analyst Ratings

TPVG

Keefe, Bruyette & Woods Upgrades TriplePoint Venture Gwth to Market Perform, Lowers Price Target to $7.5

Biotech

Earnings

Guidance

Health Care

General

CARM

CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025

<p>Stephens &amp; Co.  analyst Jim Salera   reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Overweight and maintains $62 price target.</p>


Reiteration

PZZA

Stephens & Co. Reiterates Overweight on Papa John's International, Maintains $62 Price Target

WIIM

KVYO

Klaviyo shares are trading lower. The company reported Q3 financial results.

<p>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.24) by 29.17 percent.  The company reported quarterly sales of $3.38 million which missed the analyst consensus estimate of $5.47 million by 38.08 percent.  This is a 11.55 percent decrease over sales of $3.83 million the same period last year.</p>


CARISMA Therapeutics Q3 2024 GAAP EPS $(0.31) Misses $(0.24) Estimate, Sales $3.38M Miss $5.47M Estimate

MRNA

Moderna shares are trading higher after the company reported better-than-expected Q3 sales results.

<p>Burford Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) reported quarterly earnings of $0.61 per share which missed the analyst consensus estimate of $0.92 by 33.7 percent.  The company reported quarterly sales of $249.114 million which missed the analyst consensus estimate of $393.893 million by 36.76 percent.  This is a 32.47 percent decrease over sales of $368.873 million the same period last year.</p>


Earnings Misses

Burford Capital Q3 2024 GAAP EPS $0.61 Misses $0.92 Estimate, Sales $249.114M Miss $393.893M Estimate

<p>Chicago Atlantic Real Estate Finance, Inc<em>.</em>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) <a href="https://www.globenewswire.com/en/news-release/2024/11/07/2976505/0/en/Chicago-Atlantic-Real-Estate-Finance-Announces-Third-Quarter-2024-Financial-Results.html">announced</a> strong third-quarter results for 2024. The company, a commercial mortgage real estate investment trust (REIT) specializing in cannabis-related assets, reported significant net income growth and expanding portfolio performance, underpinned by disciplined loan management.</p>
<h3 class="wp-block-heading"><strong>Key Financial Highlights for Q3 2024</strong></h3>
<ul>
<li><strong>Net Interest Income:</strong>&nbsp;$14.5 million, up from $13.2 million in Q2 2024 and a 9.1% increase from Q3 2023.</li>
<li><strong>Net Income:</strong>&nbsp;$11.2 million, or $0.56 per share, a 21.7% sequential increase and a 19% year-over-year increase.</li>
<li><strong>Distributable Earnings:</strong>&nbsp;$11.2 million, or $0.56 per share, reflecting a 12% quarterly increase and a 15% year-over-year rise.</li>
<li><strong>Book Value:</strong>&nbsp;$15.05 per share, up slightly from $14.92 in <a href="https://www.benzinga.com/markets/cannabis/24/08/40228072/cannabis-reit-chicago-atlantic-nets-9-2m-in-strong-q2-citing-regulatory-tailwinds">Q2 2024</a>, showing growth in shareholder equity.</li>
</ul>
<h3 class="wp-block-heading"><strong>Portfolio And Investment Activity</strong></h3>
<p>As of September 30, 2024, Chicago Atlantic's portfolio included<strong> $362.3 million in <a href="https://www.benzinga.com/markets/cannabis/24/10/41496393/chicago-atlantic-secures-bbb-rating-and-50m-loan-to-enhance-liquidity-in-cannabis-lending">loan principal </a>across 29 companies</strong>, with a real estate collateral coverage of 1.2x, slightly down from 1.3x in June. </p>
<p>The company originated $32.7 million in gross loans during Q3, including $24 million to new borrowers and $8.7 million to existing ones, with a weighted average yield to maturity of 18.3%. </p>
<p>After the quarter's close, Chicago Atlantic funded an additional $36.5 million, including a $25 million credit facility with an Illinois operator.</p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</em></strong></li>
</ul>
<p>"We have managed our portfolio and its maturities very well throughout 2024 with extensions, modifications, and refinancings, while improving credit quality and loan coverage,&#8221; stated co-CEO <strong><a href="https://www.benzinga.com/markets/cannabis/24/10/41237545/exclusive-weed-companies-will-be-treated-like-normal-businesses-once-this-tax-provision-goes-awa">Peter Sack</a></strong>. &#8220;A strong pipeline in both existing and new states with adult-use legislation keeps us well-positioned for the balance of the year and into 2025."</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41237545/exclusive-weed-companies-will-be-treated-like-normal-businesses-once-this-tax-provision-goes-awa">EXCLUSIVE: Weed Companies Will Be Treated Like Normal Businesses Once This Tax Provision Goes Away, Experts Say</a></strong></p>
<h3 class="wp-block-heading"><strong>Capital And Liquidity Management</strong></h3>
<p>During Q3, Chicago Atlantic increased its secured revolving credit facility to $110 million, with a drawdown of $54 million as of quarter-end, resulting in a leverage ratio of 18%. </p>
<p>In October, the company secured a $50 million unsecured term loan with a fixed interest rate of 9.0% and received an investment-grade BBB+ rating from Egan-Jones. This loan strengthens Chicago Atlantic's liquidity, leaving $94.5 million available under the facility and approximately $80 million in total liquidity as of early November.</p>
<p>The company also paid a quarterly dividend of $0.47 per share on October 15, reflecting its steady return to shareholders amid robust performance.</p>
<h3 class="wp-block-heading"><strong>REFI Stock Price Action</strong></h3>
<p>REFI shares closed Wednesday at <strong>$15.58</strong> per share gaining +0.33 during the trading session, which represents a 2.16% increase.</p>
<ul>
<li><strong>Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40607517/delivering-returns-as-the-cannabis-market-tanks-what-wall-st-wont-tell-you-about-ch">Delivering Returns As The Cannabis Market Tanks: What Wall St Won&#8217;t Tell You About Chicago Atlantic Real Estate&#8217;s Growth</a></strong></li>
</ul>
<p><em>COVER: AI Generated Image</em></p>


Cannabis

Markets

REFI

Chicago Atlantic Real Estate Net Income Increases 19% YoY, Expands Cannabis Loan Portfolio

<p>Vertical Research   upgrades Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) from Hold to Buy and announces $109 price target.</p>


Vertical Research Upgrades Intl Flavors & Fragrances to Buy, Announces $109 Price Target

<p>HC Wainwright &amp; Co.  analyst Kevin Dede   maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and raises the price target from $15 to $17.</p>


Core Scientific, Inc. - Class A Common Stock

CORZ

HC Wainwright & Co. Maintains Buy on Core Scientific, Raises Price Target to $17

United States Cellular shares are trading higher after the company announced an agreement with AT&T to sell a portion of its retained spectrum licenses for $1.018 billion.

Dividends

CCOI

Cogent Communications Raises Dividend From $0.985 To $0.995

PRTH

Priority Technology Holdings shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

Turning Point Brands shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its guidance.

<p><strong>Clear Channel Outdoor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) released its Q3 earnings on Thursday, October 31, 2024 at 06:00 AM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.</p>
<p>Revenue was up $32.20 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.01 in the last quarter, resulting in a 3.0% drop share price change the following day.</p>
<p>Here's a look at Clear Channel Outdoor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>
</p>
<h3>Latest Earnings Reports from Competitors</h3>
<p>With Clear Channel Outdoor's earnings data now available, it's crucial to gauge how its competitors, including PubMatic, TechTarget, and National CineMedia, have been performing.</p>
<ul>
<li>PubMatic's earnings announcement on August 08, 2024 exceeded expectations, with an actual EPS of $0.17 compared to the market's projected EPS of $-0.02, resulting in a 950.0% increase.</li>
<li>TechTarget's earnings on August 08, 2024 exceeded market projections, revealing an EPS of $0.42 compared to the estimated EPS of $0.4, resulting in a 5.0% increase.</li>
<li>National CineMedia announced earnings on November 05, 2024, revealing results below market expectations. Despite the market's anticipation of an EPS of $-0.03, National CineMedia's actual EPS was $-0.04, resulting in a -33.33% decrease compared to expectations.</li>
</ul>
<h3>Competitors Quarterly Earnings and Stock Performance Analysis</h3>
<p>In this detailed analysis, insights are provided into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>
</p>
<h3>Comparative Study: Estimated vs. Actual Peer Revenues</h3>
<p>Below is a comparison of estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison gives insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Clear Channel Outdoor Q3 Earnings Assessment

MTSI

MACOM Technology Solutions shares are trading higher after the company reported Q4 EPS in line with estimates and sales that beat expectations.

EPAM

EPAM Systems shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance above estimates. Also, the company issued better-than-expected Q4 revenue guidance and Adj. EPS guidance with its midpoint above estimates.

<p>MoneyLion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $0.20 by 225 percent.  The company reported quarterly sales of $135.466 million which beat the analyst consensus estimate of $135.208 million by 0.19 percent.  This is a 22.86 percent increase over sales of $110.258 million the same period last year.</p>


Earnings Beats

MoneyLion Q3 2024 GAAP EPS $(0.25) Misses $0.20 Estimate, Sales $135.466M Beat $135.208M Estimate

Hilton Grand Vacations shares are trading higher after the company reported Q3 EPS in line with estimates and sales that beat expectations.

<p>Compass Point  analyst Dominick Gabriele   upgrades AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) from Neutral to Buy and raises the price target from $8 to $15.</p>


AVDX

Compass Point Upgrades AvidXchange Holdings to Buy, Raises Price Target to $15

An announcement from Avid Bioservices ( ($CDMO) ) is now available. Avid Bioservices, Inc. has reported a strong start to fiscal 2025 with first-qu...

Avid Bioservices Reports Growth and Strong Pipeline

Avid Bioservices, Inc. (CDMO) Q1 2025 Earnings Call Transcript

In a report released yesterday, Sean Dodge from RBC Capital maintained a Buy rating on Avid Bioservices (CDMO – Research Report), with a price targ...

RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)

Avid Bioservices stock rallies 18% after reporting increased backlog

Avidity Biosciences: Good Prospects, But We Are A Little Late

Avid Bioservices ( ($CDMO) ) has shared an update. At Avid Bioservices' 2024 Annual Meeting, stockholders approved significant amendments to the 20...

Avid Bioservices' Strategic Shareholder and Governance Updates

16:55 EST Avid Bioservices (CDMO) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breakin...

Avid Bioservices trading halted, news pending

18:35 EST Avid Bioservices (CDMO) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Avid Bioservices trading resumes

Avid Bioservices (CDMO), GHO Capital Partners LLP and Ampersand Capital Partners announced they have entered into a definitive merger agreement for...

GHO Capital / Ampersand Capital to acquire Avid Bioservices for $12.50 per share

RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company anno...

Comments

Avid Bioservices

Avid Bioservices (CDMO) Opzioni

Avid Bioservices (NASDAQ:CDMO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO